camoteskimab (AVTX-007) / Avalo Therap, AstraZeneca, Apollo Therap - LARVOL DELTA

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=62 | Completed | Sponsor: Apollo Therapeutics Ltd | Active, not recruiting ➔ Completed

Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Apollo Therapeutics...announces positive results from its 32-week CHAMELEON phase 2a clinical trial of camoteskimab (an anti-IL-18 mAb that degrades IL-18 through an antibody recycling mechanism) in patients with moderate to severe atopic dermatitis (Apollo Therapeutics) - "The double-blind, randomized, placebo-controlled trial (n=62) demonstrated clinically meaningful efficacy, achieving a statistically significant reduction in EASI (Eczema Area and Severity Index) PCFB (percentage change from baseline) at week 16 compared to placebo. EASI scores clearly separated from placebo by week 4, demonstrating rapid onset of action...Camoteskimab was extremely well tolerated with no treatment-related serious adverse events or discontinuations."

P2a data • Atopic Dermatitis

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=62 | Active, not recruiting | Sponsor: Apollo Therapeutics Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Apollo Therapeutics Ltd

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=13 | Completed | Sponsor: Avalo Therapeutics, Inc. | Phase classification: P1b ➔ P1

Phase classification • Hematological Malignancies • Multiple Myeloma • Oncology

A Study to Evaluate Camoteskimab in Participants With Still's Disease (clinicaltrials.gov) - P1b | N=5 | Terminated | Sponsor: Apollo Therapeutics Ltd | Phase classification: P1b/2a ➔ P1b | N=20 ➔ 5 | Recruiting ➔ Terminated; Sponsor discretion

Enrollment change • Phase classification • Trial termination • Immunology • CRP

A Study to Evaluate Camoteskimab in Participants With Still's Disease (AOSD/sJIA) (clinicaltrials.gov) - P1b/2a | N=20 | Recruiting | Sponsor: Apollo Therapeutics Ltd | Phase classification: P1b ➔ P1b/2a | N=12 ➔ 20 | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Sep 2023 ➔ Dec 2024

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Idiopathic Arthritis • Immunology • Rheumatology • CRP • IL18

A Study to Evaluate AEVI-007 in Participants With Adult Onset Still's Disease (clinicaltrials.gov) - P1b | N=12 | Recruiting | Sponsor: Apollo Therapeutics Ltd | Trial completion date: Mar 2022 ➔ Dec 2023 | Trial primary completion date: Mar 2022 ➔ Sep 2023

Trial completion date • Trial primary completion date • Immunology • CRP

"$AVTX Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics https://t.co/PSjsbd4We4" (@stock_titan)

IL18

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1b | N=13 | Completed | Sponsor: Avalo Therapeutics, Inc. | Recruiting ➔ Completed | N=30 ➔ 13 | Trial completion date: Jun 2022 ➔ Mar 2022

Enrollment change • Trial completion • Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1b; N=30; Recruiting; Sponsor: Cerecor Inc; Trial completion date: Aug 2021 ➔ Jun 2022; Trial primary completion date: Aug 2021 ➔ Mar 2022

Clinical • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

A Study to Evaluate AEVI-007 in Participants With Adult Onset Still's Disease (clinicaltrials.gov) - P1b; N=12; Recruiting; Sponsor: Cerecor Inc; Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • CRP

A Study to Evaluate AEVI-007 in Participants With Adult Onset Still's Disease (clinicaltrials.gov) - P1b; N=12; Not yet recruiting; Sponsor: Cerecor Inc

Clinical • New P1 trial • CRP

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1b; N=30; Recruiting; Sponsor: Aevi Genomic Medicine, LLC, a Cerecor company; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology • CD38

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1b; N=30; Not yet recruiting; Sponsor: Aevi Genomic Medicine, LLC, a Cerecor company

Clinical • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for Treatment of Relapsed or Refractory Multiple Myeloma (GlobeNewswire) - “Cerecor Inc…announced that its Investigational New Drug Application (IND) to study the use of CERC-007 to treat relapsed or refractory multiple myeloma (MM) has been accepted by the United States Food and Drug Administration (FDA) and is now open. The first study will be a U.S. multicenter Phase 1b clinical trial. Initial data is expected in the first quarter of 2021….The planned Phase 1b clinical trial is a U.S. multicenter, open-label, dose-escalation, sequential group study of CERC-007 as a monotherapy in approximately 30 patients with relapsed or refractory MM.”

Enrollment status • IND • P1 data • Hematological Malignancies • Multiple Myeloma • Oncology

Cerecor Announces First Patient Dosed in a Phase 1b Clinical Trial of CERC-007 for the Treatment of Relapsed or Refractory Multiple Myeloma (GlobeNewswire) - “Cerecor Inc…announced that it has dosed its first patient in a Phase 1b clinical trial of CERC-007. CERC-007 is a high affinity, fully human anti-IL-18 monoclonal antibody (mAb) being developed for patients with relapsed or refractory multiple myeloma (MM). The study will determine the recommended Phase 2 dose, safety and preliminary efficacy of CERC-007. The Company anticipates initial data to be reported in the first quarter of 2021.”

P1 data • Trial status • Hematological Malignancies • Multiple Myeloma • Oncology